{"organizations": [], "uuid": "87993d3daafdaf5e4a3cfeb31808f2d347df6452", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-arena-pharmaceuticals-reports-posi/brief-arena-pharmaceuticals-reports-positive-phase-2-results-for-oasis-trial-for-etrasimod-idUSB8N1K800T", "country": "US", "domain_rank": 408, "title": "BRIEF-Arena Pharmaceuticals Reports Positive Phase 2 Results For Oasis Trial For Etrasimod", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-19T22:50:00.000+02:00", "replies_count": 0, "uuid": "87993d3daafdaf5e4a3cfeb31808f2d347df6452"}, "author": "", "url": "https://www.reuters.com/article/brief-arena-pharmaceuticals-reports-posi/brief-arena-pharmaceuticals-reports-positive-phase-2-results-for-oasis-trial-for-etrasimod-idUSB8N1K800T", "ord_in_thread": 0, "title": "BRIEF-Arena Pharmaceuticals Reports Positive Phase 2 Results For Oasis Trial For Etrasimod", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-arena pharmaceuticals reports positive phase", "sentiment": "negative"}, {"name": "oasis trial for etrasimod reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "reuters) - arena pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 19, 2018 / 8:53 PM / in 9 minutes BRIEF-Arena Pharmaceuticals Reports Positive Phase 2 Results For Oasis Trial For Etrasimod Reuters Staff 1 Min Read March 19 (Reuters) - Arena Pharmaceuticals Inc: * ARENA PHARMACEUTICALS REPORTS POSITIVE PHASE 2 RESULTS FOR THE OASIS TRIAL FOR ETRASIMOD IN PATIENTS WITH ULCERATIVE COLITIS * HIGH DOSE ETRASIMOD GROUP ACHIEVED STATISTICALLY SIGNIFICANT IMPROVEMENT IN CLINICAL REMISSION IN STUDY * TRIAL MET PRIMARY, SECONDARY ENDPOINTS WITH STATISTICAL SIGNIFICANCE FOR PATIENTS GETTING HIGH DOSE ETRASIMOD FOR 12 WKS * ETRASIMOD WAS WELL TOLERATED, HAD FEWER PATIENTS WITH SERIOUS ADVERSE EVENTS VERSUS PLACEBO IN STUDY * IMPACT ON HEART RATE, ATRIOVENTRICULAR (AV) CONDUCTION LOW IN STUDY WITH NO DISCONTINUATIONS RELATED TO BRADYCARDIA OR AV BLOCK * NO INCREASES IN LIVER FUNCTION TESTS VERSUS PLACEBO, NO REPORTS OF MACULAR EDEMA OR PULMONARY FUNCTION TEST ABNORMALITIES IN STUDY * INTENDS TO INITIATE PHASE 3 PROGRAM IN ULCERATIVE COLITIS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-19T22:50:00.000+02:00", "crawled": "2018-03-19T23:08:42.001+02:00", "highlightTitle": ""}